Company intelligence / Profile preview

AmRNA

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

AmRNA (Advanced mRNA) is a biotechnology company specializing in the development of next-generation messenger RNA (mRNA) therapeutics and vaccines. The company leverages a proprietary platform for mRNA synthesis and lipid nanoparticle (LNP) delivery to address unmet needs in oncology, infectious diseases, and rare genetic disorders. By optimizing mRNA stability and translation efficiency, AmRNA aims to create more potent and durable treatments compared to first-generation mRNA technologies. Their approach focuses on both linear and potentially circular RNA architectures to expand the therapeutic window of RNA-based medicine.

Therapeutic areas: Infectious DiseasesRare DiseasesOncology
Modalities: mRNA-based drugsLipid nanoparticle delivery therapy
Industry: Biotech

Beyond the preview

Go deeper on AmRNA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AmRNA.

Explore the full profile